Ascletis Pharma's (HKG:1672) attributed losses in 2024 widened year on year to 300.9 million yuan or 0.3005 yuan per share from 144.7 million yuan or 0.1347 yuan per share, according to a Hong Kong Stock Exchange disclosure on Wednesday.
The biotechnology company's revenue plummeted to 1.3 million yuan from 56.6 million yuan a year earlier.
The company's shares closed 10% lower.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.